XML 76 R20.htm IDEA: XBRL DOCUMENT v3.2.0.727
Segment, Customer and Geographic Information
 6 Months Ended
Jun. 30, 2015
Segment, Customer and Geographic Information

Note 14. Segment, Customer and Geographic Information

The Company continues to operate in only one segment, blood safety. The Company’s chief executive officer is the chief operating decision maker who evaluates performance based on the net revenues and operating loss of the blood safety segment. The Company considers the sale of all of its INTERCEPT Blood System products to be similar in nature and function, and any revenue earned from services is minimal.

The Company’s operations outside of the U.S. include a wholly-owned subsidiary headquartered in Europe. The Company’s operations in the United States of America are responsible for the research and development and global and domestic commercialization of the INTERCEPT Blood System, while operations in Europe are responsible for the commercialization efforts of the platelet and plasma systems in Europe, the Commonwealth of Independent States and the Middle East. Product revenues are attributed to each region based on the location of the customer, and in the case of non-product revenues, on the location of the collaboration partner.

 

The Company had the following significant customers that accounted for more than 10% of the Company’s total product revenue, all of which operate in a country outside of the United States of America, during the three and six months ended June 30, 2015 and 2014 (in percentages):

 

     Three Months Ended
June 30,		     Six Months Ended
June 30,		  
     2015     2014     2015     2014  

Etablissement Francais du Sang

      25 %      24 %      25 %      24 % 

Advanced Technology Company KSC

      *        18 %      *        *   

Medical Device APS

      *        10 %      *        *   

 

* Represents an amount less than 10% of product revenue.